Human Wound Dressing
Bacterial wound infections
Approved (FDA De Novo)Active
Key Facts
Indication
Bacterial wound infections
Phase
Approved (FDA De Novo)
Status
Active
Company
About Amferia Kills Bacteria
Amferia has developed a patented hydrogel platform that stabilizes and delivers antimicrobial peptides (AMPs) to kill bacteria, including antibiotic-resistant strains, through a physical membrane-disruption mechanism. The company's core innovation protects the fragile peptides from enzymatic degradation, enabling sustained antibacterial activity for up to five days. With its first veterinary product launched in Europe and a key FDA De Novo clearance for a human wound dressing, Amferia is transitioning from R&D to commercialization. Its platform has broad potential applications across wound care, surgical coatings, and antimicrobial sprays.
View full company profile